Vimta Labs Ltd
Vimta Labs Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
The short version
Vimta Labs aims for 20% to 25% growth in sales/revenue for the full year (Q1 was impacted by Middle East crisis). Vimta Labs aims to maintain or exceed a 20%-25% growth rate in revenue for the current and upcoming years, reflecting confidence in sustainable growth.
From Vimta Labs Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Vimta Labs aims for 20% to 25% growth in sales/revenue for the full year (Q1 was impacted by Middle East crisis).
- Despite Q1 challenges, the company remains optimistic and confident about growth over the next few quarters and the full year.
- The company's various business units are growing at almost double the industry's CAGR (8%-11%).
- Positive enquiry trends quarter-on-quarter signal improving demand conditions.
- Expansion in pharma services, especially export to the U.S., is expected to contribute significantly.
- New biologics segment expected to contribute meaningfully from the third year onwards.
2 more points from Vimta Labs Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Vimta Labs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Vimta Labs has a planned capex of approximately INR 80 crores for FY27.
- Around INR 20 crores have already been spent on the Biologics segment, with a remaining INR 10 crores planned for this year.
- The capex includes about INR 40 crores invested in the Electronics and Electrical testing segment.
- The majority of the INR 80 crores capex is for routine operations across various business units, with only a portion allocated to Biologics.
- Capital investments are phased based on business visibility, customer demand, and project needs.
2 more points from Vimta Labs Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Vimta Labs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has secured its first order in the new Biologics vertical, with commercialization having begun in Q1 FY27.
- Details of the Biologics order, including size and customer specifics, are confidential and not disclosed.
- The timeline for conversion of other client discussions into orders is variable, depending on project stages.
- The management expressed a positive outlook on the enquiry trend, indicating a healthy pipeline both domestically and internationally, especially in the U.S. pharma services market.
2 more points from Vimta Labs Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Vimta Labs Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹109 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Vimta Labs Ltd's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY23 earnings call →
Others in Healthcare Services this season
- Aatmaj Healthcare Ltd (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- 3B Blackbio (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
- Thyrocare Tech. (Q1 FY27)
Pathology business grew ~27%; franchisee business grew ~23-27% YoY, reflecting strong volume growth. Key concall takeaways from Thyrocare Technologies Ltd's Q1…
Arthneeti Pro · Annual
Vimta Labs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Vimta Labs Ltd Q1 FY27 results?
Vimta Labs aims for 20% to 25% growth in sales/revenue for the full year (Q1 was impacted by Middle East crisis). Vimta Labs aims to maintain or exceed a 20%-25% growth rate in revenue for the current and upcoming years, reflecting confidence in sustainable growth.
What is Vimta Labs Ltd share price analysis?
Vimta Labs Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 34.8 with a market cap of ₹2,814 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vimta Labs Ltd planning capital expenditure?
Vimta Labs has a planned capex of approximately INR 80 crores for FY27. - Around INR 20 crores have already been spent on the Biologics segment, with a remaining INR 10 crores planned for this year. - The capex includes about INR 40 crores invested in the Electronics and Electrical testing segment. - The majority of the INR 80 crores capex is for routine operations across various business units, with only a portion allocated to Biologics. - Capital investments are phased based on business visibility, customer demand, and project needs. - The company has created around 200,000 sq.
Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.